18/02/26 -"A Surprising Tactical Error by the Board"
SANOFI
AlphaBlunt!
18/02/26 -"A Surprising Tactical Error by the Board"
• Sanofi’s Board has selected an experienced senior executive to lead the transformation.
The Board itself lacks the expertise and experience required for a group constrained by its R&D timeline.
• The risks are understood by governance (removal of Mr. Hudson), but the response does not appear likely to mitigate them.
AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.
| Corporate broking | NO |
| Trading in corporate shares | NO |
| Analyst ownership | NO |
| Advising of corporate (strategy, marketing, debt, etc) | NO |
| Research paid for by corporate | NO |
| Provision of corporate access paid for by corporate | NO |
| Link between and a banking entity | NO |
| Brokerage activity at AlphaValue | NO |